Document Type
Article
Original Publication Date
2016
Journal/Book/Conference Title
Basic to Translational Science
Volume
1
Issue
6
DOI of Original Publication
10.1016/j.jacbts.2016.06.012
Date of Submission
February 2017
Abstract
Despite therapeutic advances, acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. One potential limitation of the current treatment paradigm is the lack of effective therapies to optimize reperfusion after ischemia and prevent reperfusion-mediated injury. Experimental studies indicate that this process accounts for up to 50% of the final infarct size, lending it importance as a potential target for cardioprotection. However, multiple therapeutic approaches have shown potential in pre-clinical and early phase trials but a paucity of clear clinical benefit when expanded to larger studies. Here we explore this history of trials and errors of the studies of cyclosporine A and other mitochondrial membrane permeability inhibitors, agents that appeared to have a promising pre-clinical record yet provided disappointing results in phase III clinical trials.
Rights
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Is Part Of
VCU Internal Medicine Publications
Comments
Originally published at http://dx.doi.org/10.1016/j.jacbts.2016.06.012.
Funded in part by the VCU Libraries Open Access Publishing Fund.